PROK (ProKidney Inc.) Future Price to Earnings

Brandmark of prokidney.com (PROK)

ProKidney Corp. is developing innovative kidney therapies whose success depends on scientific breakthroughs rather than market cycles. The company's forward P/E ratio reflects market yield expectations, where the value of 0.00 characterizes this level. International conflicts are complicating patent protection and component supplies. The absence of commercial products temporarily deprives the company of pricing power over its services.

PROK - prokidney.com Market Cap to Projected Earnings over the range 04/28/2023 - 11/13/2026

ProKidney Pharma (PROK) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Quotes ProKidney|PROK - Fair Value Consensus
- business market valuation indicators:
Market Value ProKidney Corp|PROK - Enterprise Value
- balance sheet equity data:
Book Value per Share ProKidney|PROK - Book Valuation of Business|Market Capitalization to Book Value Ratio prokidney.com|PROK - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity ProKidney Corp.|PROK - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital ProKidney Corp.|PROK - Company Cumulative Debt|Debt to Book Value ProKidney Corp|PROK - Long-Term Debt|Company Short-Term Debt ProKidney|Quick Liquidity prokidney.com
- earnings and market ratios statistics:
PROK - Final Profit|Expected Profit ProKidney Corp.|PROK - Market Cap to Earnings|Future Price to Earnings ProKidney Inc.|PROK - PEG Multiple|EV/EBITDA Multiple ProKidney Corp|PROK - Operating income before deduction of amortization|Net earnings per share (EPS TTM) ProKidney|PROK - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months prokidney.com|PROK - Earnings per share growth this year|Earnings growth forecast for next year ProKidney Corp.
Analysis of all company metrics:ProKidney PROK
Signature product of ProKidney Pharma

ProKidney Corp. (PROK) is advancing regenerative nephrology through strategic alliances and cell therapy. This indicator compares the current market value of the business with expected future earnings. By analyzing the historical trend of the company's forward P/E ratio, an investor can observe the dynamics of market expectations relative to fundamental value. An increase in this metric reflects the research success already priced in, while a decrease in the value signals improved price stability.

Competitors of ProKidney Corp. (PROK)

Projected Price to Earnings TVTX (Travere Therapeutics, Inc.)|ARDX (Ardelyx Inc) - Future Price to Earnings Multiple|Future Price to Earnings Akebia AKBA|Forward P/E Multiple Cara Corp TVRD|DiaMedica Therapeutics - Forward P/E Multiple|Market Cap to Projected Earnings unicycive.com UNCY|RMTI: Forward P/E Multiple|Price to Future Earnings Ratio CVKD|Future Price to Earnings Conduit Pharma|Price to Future Earnings Ratio CALT (Calliditas)|Forward P/E Multiple RNLX|ZVSA - Projected Price to Earnings Ratio